Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
$20.27
-0.4%
$20.47
$13.30
$30.03
$1.20B0.93375,349 shs589,226 shs
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
$5.06
+1.0%
$5.31
$2.94
$10.25
$286.04M3.05127,482 shs77,547 shs
Precigen, Inc. stock logo
PGEN
Precigen
$4.51
-0.9%
$2.10
$0.65
$4.82
$1.34B1.873.83 million shs9.09 million shs
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$7.83
-0.9%
$5.81
$2.48
$8.02
$1.26B0.652.55 million shs1.51 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-1.55%+2.62%+1.44%+14.13%-9.11%
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
-7.39%-0.60%-15.23%+21.01%-34.08%
Precigen, Inc. stock logo
PGEN
Precigen
-0.87%+25.00%+189.81%+244.70%+302.65%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-1.13%+4.08%+58.00%+60.24%+183.15%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
2.6183 of 5 stars
3.52.00.00.02.04.20.0
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
2.8988 of 5 stars
3.63.00.00.02.91.70.6
Precigen, Inc. stock logo
PGEN
Precigen
3.8428 of 5 stars
3.40.00.04.73.01.70.6
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
3.5268 of 5 stars
1.43.00.04.24.02.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
3.00
Buy$41.20103.26% Upside
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
3.17
Buy$10.67110.80% Upside
Precigen, Inc. stock logo
PGEN
Precigen
2.80
Moderate Buy$8.2582.93% Upside
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
2.83
Moderate Buy$7.08-9.54% Downside

Current Analyst Ratings Breakdown

Latest FHTX, XERS, PGEN, and ELVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/19/2025
Precigen, Inc. stock logo
PGEN
Precigen
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
8/19/2025
Precigen, Inc. stock logo
PGEN
Precigen
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$6.00 ➝ $8.00
8/19/2025
Precigen, Inc. stock logo
PGEN
Precigen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.50
8/19/2025
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$7.00 ➝ $9.00
8/15/2025
Precigen, Inc. stock logo
PGEN
Precigen
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderweight ➝ Neutral
8/13/2025
Precigen, Inc. stock logo
PGEN
Precigen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00
8/12/2025
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$10.00
7/2/2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$40.00 ➝ $48.00
6/16/2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$40.00 ➝ $52.00
6/16/2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$37.00
6/12/2025
Precigen, Inc. stock logo
PGEN
Precigen
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$6.00
(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/A$8.25 per shareN/A
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
$24.17M11.83N/AN/A($1.36) per share-3.72
Precigen, Inc. stock logo
PGEN
Precigen
$3.92M342.82N/AN/A($0.12) per share-37.58
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$203.07M6.23N/AN/A($0.12) per share-65.25
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$89.02M-$2.00N/AN/AN/AN/A-29.15%-27.88%11/12/2025 (Estimated)
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
-$86.62M-$1.19N/AN/AN/A-311.90%N/A-28.00%11/3/2025 (Estimated)
Precigen, Inc. stock logo
PGEN
Precigen
-$126.24M-$0.42N/AN/AN/A-2,868.66%-842.83%-78.98%11/13/2025 (Estimated)
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-$54.84M-$0.21N/AN/AN/A-13.01%N/A-8.00%11/14/2025 (Estimated)

Latest FHTX, XERS, PGEN, and ELVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$0.53-$0.49+$0.04-$0.49N/AN/A
8/12/2025Q2 2025
Precigen, Inc. stock logo
PGEN
Precigen
-$0.14-$0.11+$0.03-$0.09$0.67 million$0.86 million
8/7/2025Q2 2025
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-$0.03-$0.01+$0.02-$0.01$64.58 million$67.71 million
8/5/2025Q2 2025
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
-$0.31-$0.28+$0.03-$0.28$7.62 million$7.56 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/AN/A
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
N/AN/AN/AN/AN/A
Precigen, Inc. stock logo
PGEN
Precigen
N/AN/AN/AN/AN/A
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/A
32.58
32.58
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
N/A
2.62
2.62
Precigen, Inc. stock logo
PGEN
Precigen
N/A
2.71
2.71
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
N/A
1.95
1.24

Institutional Ownership

CompanyInstitutional Ownership
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
95.08%
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
61.55%
Precigen, Inc. stock logo
PGEN
Precigen
33.51%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
42.75%

Insider Ownership

CompanyInsider Ownership
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
25.90%
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
7.58%
Precigen, Inc. stock logo
PGEN
Precigen
47.10%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
6.47%
CompanyEmployeesShares OutstandingFree FloatOptionable
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
5059.24 million43.89 millionOptionable
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
12056.53 million52.25 millionOptionable
Precigen, Inc. stock logo
PGEN
Precigen
190297.97 million157.63 millionOptionable
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
290161.48 million151.03 millionOptionable

Recent News About These Companies

Xeris Biopharma Holdings, Inc. (XERS) Reports Record $71.5M Q2 Revenue
FY2025 EPS Estimate for Xeris Biopharma Increased by Analyst
Q3 EPS Estimates for Xeris Biopharma Lowered by Analyst
HC Wainwright Estimates Xeris Biopharma Q3 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Enliven Therapeutics stock logo

Enliven Therapeutics NASDAQ:ELVN

$20.27 -0.09 (-0.44%)
Closing price 04:00 PM Eastern
Extended Trading
$20.27 0.00 (0.00%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Foghorn Therapeutics stock logo

Foghorn Therapeutics NASDAQ:FHTX

$5.06 +0.05 (+1.00%)
Closing price 04:00 PM Eastern
Extended Trading
$5.07 +0.01 (+0.20%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Precigen stock logo

Precigen NASDAQ:PGEN

$4.51 -0.04 (-0.88%)
Closing price 04:00 PM Eastern
Extended Trading
$4.58 +0.07 (+1.44%)
As of 05:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Xeris Biopharma stock logo

Xeris Biopharma NASDAQ:XERS

$7.83 -0.07 (-0.89%)
Closing price 04:00 PM Eastern
Extended Trading
$7.78 -0.05 (-0.64%)
As of 05:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.